Cohort studies may underestimate rare vaccine adverse events: evidence from stroke incidence following COVID-19 vaccination.

Cohort studies may underestimate rare vaccine adverse events: evidence from stroke incidence following COVID-19 vaccination.

Publication date: Dec 01, 2026

The self-controlled case series (SCCS) design is widely used for short-term vaccine safety assessment but allows only indirect estimation of absolute risk differences. This study evaluated whether absolute measures should be estimated exclusively using cohort designs by comparing excess stroke incidence following COVID-19 vaccination in a nationwide cohort with previous estimates from an SCCS analysis. A nationwide retrospective cohort study was conducted in Qatar between 1 December 2020 and 11 April 2023. Stroke incidence during the 42 days following vaccination was compared between 1,111,939 vaccinated persons and an equal number of individually matched unvaccinated persons. During follow-up, 8 strokes occurred in the vaccinated cohort and 19 in the unvaccinated cohort, corresponding to incidence rates of 0. 2 (95% CI, 0. 1-0. 3) and 0. 4 (95% CI, 0. 2-0. 6) per 100,000 person-weeks, respectively. The adjusted hazard ratio comparing vaccinated with unvaccinated individuals was 0. 42 (95% CI, 0. 18-0. 96). These cohort findings suggesting a spurious protective effect contrast with SCCS results from the same and other populations, which indicate a small increase in post-vaccination stroke risk. This divergence may reflect healthy vaccinee bias in between-person comparisons, challenging the exclusive use of cohort designs for estimating absolute risk differences.

Open Access PDF

Concepts Keywords
Adult
Aged
Bias
cerebrovascular disorders
Cohort Studies
COVID-19
COVID-19 Vaccines
COVID-19 Vaccines
Female
healthy vaccinee effect
Humans
immunity
immunization
Incidence
Male
Middle Aged
Qatar
Retrospective Studies
self-controlled case-series
Stroke
Unvaccinated Persons
Vaccination
vaccine

Semantics

Type Source Name
disease MESH stroke
disease MESH COVID-19
drug DRUGBANK Aspartame
drug DRUGBANK Coenzyme M
disease MESH cerebrovascular disorders
drug DRUGBANK Cysteamine
disease MESH ect
pathway REACTOME Reproduction
disease MESH severe acute respiratory syndrome
disease MESH cap
disease MESH death
disease MESH acute ischemic stroke
disease MESH hemorrhagic stroke
disease MESH hos
disease MESH mRS
disease MESH infection
drug DRUGBANK Isoxaflutole
disease MESH SMDs
disease MESH SMD
pathway KEGG Coronavirus disease
disease MESH face
disease MESH frailty
disease MESH influenza
disease MESH injury
disease MESH neonatal herpes
drug DRUGBANK Esomeprazole
drug DRUGBANK Gold
disease MESH pds
disease MESH Herpes zoster
disease MESH deep vein thrombosis
disease MESH pulmonary embolism
disease MESH bleeding
disease MESH CRC
disease MESH tics
drug DRUGBANK (S)-Des-Me-Ampa
disease MESH Dis
disease MESH emergency
disease MESH cerebral infarction
disease MESH reinfection
disease MESH thrombocytopenia
disease MESH thromboembolism
disease MESH Thrombosis
disease MESH coronavirus infection

Original Article

(Visited 6 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *